Despite a $2.5 million check from a vaccine alliance earlier this summer, Codiak BioSciences is still struggling. The biotech is laying off around 30 employees and trimming its pipeline.

The hemophilia A market has a new date for the diary: Feb. 28. Officials at the FDA put the date on the agenda at Sanofi and Sobi by accepting the partners’ hemophilia A drug candidate efanesoctocog alfa for priority review.

After achieving its main phase 2 trial goal, Alnylam’s immunoglobulin A nephropathy (IgAN) treatment has now hit several secondary endpoints, demonstrating further potential for the Regeneron-partnered therapeutic as the companies aim to catch up to Calliditas Therapeutics’ approved med Tarpeyo.

This year’s annual meeting of the European Society of Cardiology, set in Barcelona, Spain, carried a special spotlight on the growing power of cardiac imaging. Handheld ultrasounds, CT and MRI scans are offering new ways to see the heart’s inner workings. They are helping change the way clinicians track down cardiovascular disease and ultimately treat patients—whether they’re in the same room or not.

Medtronic has put forward a clinical study showing the success of a new type of minimally invasive defibrillator implant designed to interrupt a sudden cardiac arrest.

Arch Venture Partners is bankrolling a biotech that could render high-throughput screening obsolete. The biotech, Vilya, starts life with a $50 million, Arch-led series A round and technology to design a new class of medicines.

A groundswell of interest in Bristol Myers Squibb’s anticoagulant milvexian to prevent secondary stroke has been building ever since the drug turned heads in late 2021 based on promising data in blood clots. Now, an interim analysis of the phase 2 trial is finally seeing the light of day, but it’s more of a mixed bag this time around.

In an unfortunate series of events reminiscent of those that led to the discontinuation of the HeartWare Ventricular Assist Device last year, Medtronic has now racked up a third Class I recall for the heart pump since taking it off the market.

After days of swirling speculation, Olympus finally confirmed this week that it has agreed to sell off its scientific solutions business to Bain Capital Private Equity.

About four months after beginning its hunt for a new CEO to replace Don Casey—and amid an ongoing investigation into past financial practices—Dentsply Sirona’s search is complete.